Clinical trials: Healthy Male
Renal Impairment, Healthy
A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intranasally administered esketamine in participants with impaired renal function when compared to participants with normal renal function.
- Trial name
- NCT02606084
- Testing
- Esketamine
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Renal Failure
Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment
This study will evaluate the pharmacokinetics of Lu AF35700 after a single dose tablet to subjects with renal impairment (kidney insufficiency) and compare that with healthy subjects
- Trial name
- NCT03241147
- Testing
- Lu AF35700
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants
The purpose of this study is to compare the pharmacokinetic profile of a single dose of two solid dosage formulations relative to a reference formulation (solution in polyethylene glycol-400 [PEG-400]) of JNJ-64140284 in healthy…
- Trial name
- NCT04033458
- Testing
- JNJ-64140284
- Where
- Belgium
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pharmacokinetics
Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of [14C]ZSP1273 in healthy Chinese male participants, revealing the overall…
- Trial name
- NCT05873426
- Testing
- [14C] ZSP1273
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Healthy Male Subjects, Cardiovascular Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability…
- Trial name
- NCT02632526
- Testing
- AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Impairment
Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects
This study will assess the pharmacokinetics, safety and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in healthy matched control subjects.
- Trial name
- NCT01459250
- Testing
- AGO178C
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer
A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers
This single-center, open-label study will assess the excretion balance, pharmacokinetics and metabolism of oral [14C]-labeled RO4917523 in healthy male volunteers.
- Trial name
- NCT01592890
- Testing
- RO4917523
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers
Study to determine and compare the absorption of KUC 7483 CL from different regions of the GI tract with the immediate release formulation and to compare the absorption of particulate versus solution formulations from the…
- Trial name
- NCT02259920
- Testing
- KUC 7483 CL, immediate release tablet, KUC 7483 CL, particulate formulation, KUC 7483 CL, solution formulation
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.
GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain.
- Trial name
- NCT00536497
- Testing
- GW842166X
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers
The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state
- Trial name
- NCT01679613
- Testing
- Nintedanib, Ketoconazole
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of Olodaterol and Fluconazole
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
- Trial name
- NCT01153724
- Testing
- BI 1744, Fluconazole
- Where
- Germany
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.
This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male…
- Trial name
- NCT05858788
- Testing
- SAR441566
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sanofi
Renal Impairment, Renal Insufficiency
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
This is an open-label, parallel-group study to compare the pharmacokinetics and pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with severe renal impairment and matched healthy volunteers…
- Conditions
- Renal Impairment, Renal Insufficiency, Kidney Disease, Kidney Diseases
- Trial name
- NCT02039817
- Testing
- IDN-6556
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Conatus Pharmaceuticals Inc.
Healthy
Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers
Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on the bioavailability of dabigatran etexilate, Part 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe…
- Trial name
- NCT02171546
- Testing
- Dabigatran etexilate capsules, Quinidine sulfate tablets, Fexofenadine tablets
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics and early pharmacodynamics of single rising oral doses of BI 1021958 tablets in healthy male volunteers (first-in-human trial)
- Trial name
- NCT01541488
- Testing
- BI 1021958
- Where
- Germany
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Healthy Volunteers
Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, successive cohorts design, multicenter, single dose phase I study. The primary objectives are: to evaluate the pharmacokinetics (plasma and urine) profile of P03277 following single…
- Trial name
- NCT03657784
- Testing
- P03277
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guerbet
Healthy Volunteers
Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects
The purpose of this study is to evaluate the bioequivalence (comparison of the rate and extent of the active substance into the body following single administration of the drugs) between the test product V0057 and a reference…
- Trial name
- NCT01861626
- Testing
- V0057 - A mg, Isotretinoin
- Where
- Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermatology
Healthy
Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects
To investigate whether and to what extent co-administration of multiple doses of itraconazole affect single dose pharmacokinetics of BI 425809 in healthy male subjects
- Trial name
- NCT02342717
- Testing
- BI 425809, Itraconazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations
This study is a Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1601 (40 mg or 20 mg) to HGP1705 (40 mg or 20 mg) After Multiple Administrations in Healthy…
- Trial name
- NCT03372850
- Testing
- HIP1601, HGP1705
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone
This study is to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy…
- Trial name
- NCT01662674
- Testing
- gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl extended release
- Where
- South Korea
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.